- When “Severe AD” Is Not Just AD: Eczema as the First Sign of Inborn Errors of Immunity
Aubert H et al. British Journal of Dermatology. 2026.
➜ DOI: 10.1093/bjd/ljag308
Why it matters:
Among 373 patients with genetically defined inborn errors of immunity with atopy (IEIs-A), eczema affected 50.9%, often beginning in infancy and sometimes years before severe or unusual infections. DOCK8 deficiency, STAT3 loss-of-function and FOXP3 deficiency were particularly associated with eczema.
Context and caution:
IEI-associated eczema may closely mimic classic AD: 38.4% fulfilled standard AD diagnostic criteria. Clues included severe pruritus and unusual involvement of the buttocks/genitals, palms or soles, especially with STAT3-LoF or DOCK8 deficiency.
Bottom line:
In severe pediatric AD—particularly when very early, atypical or difficult to control—genotyping is becoming an important part of the diagnostic work-up, rather than something reserved for children who have already developed recurrent infections.
- When the AD Barrier Becomes a Gateway: “Eczema Mpoxicum”
Gangal A et al. JAAD Case Reports. 2026.
➜ DOI: 10.1016/j.jdcr.2026.05.022
Why it matters:
This striking case describes a 26-year-old man with severe AD and well-controlled HIV who developed disseminated mpox involving about 80% of body surface area. His AD had previously required upadacitinib and had been complicated by recurrent eczema herpeticum, although the JAK inhibitor had been stopped 3 months earlier.
Context and caution:
The authors suggest that chronic barrier disruption, previous systemic JAK inhibition and HIV may all have contributed, but a single case cannot establish causality. The broader lesson is that severe AD may provide a permissive setting for unusual and extensive viral superinfection, beyond the familiar eczema herpeticum.
Bottom line:
In severe AD, an atypical vesiculopustular eruption should prompt consideration of mpox as well as herpesvirus infection. In patients with relevant sexual exposure risk—particularly men who have sex with men —mpox vaccination should be part of preventive care.
- Dupilumab in Real-World Prurigo Nodularis: Response Depends on What You Measure
van der Gang LF et al. Journal of the American Academy of Dermatology. 2026.
➜ DOI: 10.1016/j.jaad.2026.07.046
Why it matters:
This prospective BioDay registry followed 69 adults with difficult-to-treat PN for 52 weeks. The cohort had a convincing chronic PN phenotype: mean disease duration 12.6 years, severe baseline itch (PP-NRS 8.2) and nodular disease (IGA PN-S 3.4), with 75% previously exposed to systemic immunomodulators. Notably, 42% also had AD.
Context and caution:
The apparent efficacy depends strongly on the endpoint chosen. At week 52, 64.1% achieved a ≥4-point itch reduction, but only 28.9% reached PP-NRS ≤3; 48.3% achieved IGA PN-S 0/1, while the stringent composite of both itch control and clear/almost-clear lesions was reached by only 16.4%. Itch improved rapidly, whereas nodular lesions improved more gradually. These differences are crucial when comparing trials, real-world studies and future treat-to-target definitions.
Bottom line:
Dupilumab is effective in true, longstanding PN, including patients with or without associated AD—but in PN, as in AD, “response” and “disease control” are not synonymous, and the choice of outcome measure determines the message.
- From Skin to Heart: Is Severe AD a Risk Factor for Infective Endocarditis?
Lau O et al. British Journal of Cardiology. 2026.
➜ DOI: 10.5837/bjc.2026.017
Why it matters:
This review highlights a rare but potentially devastating complication of AD: Staphylococcus aureus infective endocarditis. Among 24 reported patients, the mean age was only 29.6 years, S. aureus accounted for 23/24 infections, the mitral valve was involved in 18/24, and 20/24 required valve surgery. The biological link is plausible: impaired barrier function, scratching and heavy S. aureus colonization may facilitate bacteraemia and subsequent cardiac seeding.
Context and caution:
The evidence remains weak: 15 of the 16 included studies were case reports, more than half originated from Japan, and only one observational cohort was identified. Therefore, this paper identifies an important clinical signal, not proof that AD itself is an independent risk factor for endocarditis.
Bottom line:
In severe or poorly controlled AD, particularly with recurrent S. aureus skin infection, persistent fever or unexplained systemic illness should not be dismissed as “just another skin infection”: bacteraemia and endocarditis deserve consideration.
- Toward an “Itch-Print”? A Bioelectronic Sensor for Pruritogenic Activity in AD
Guo L et al. Biosensors and Bioelectronics. 2026
➜ DOI: 10.1016/j.bios.2026.119064
Why it matters:
This proof-of-concept couples MRGPRX2, a receptor involved in non-histaminergic pruritic signalling, to a graphene field-effect transistor, converting receptor activation into an electrical signal. The device detected substance P at picomolar concentrations and generated a different signal with plasma from patients with AD versus healthy controls. Conceptually, this is interesting because it attempts to measure functional pruritogenic activity rather than the concentration of a single biomarker.
Context and caution:
MRGPRX2 represents only one of several itch pathways and is not specific for AD. More importantly, the clinical experiment included only 20 patients with AD and 19 highly selected healthy controls, explicitly excluding subjects with other allergic or pruritic disorders. Thus, the impressive AUC of 0.97 cannot establish that the sensor distinguishes AD from chronic prurigo, urticaria, contact dermatitis or other itchy diseases. Reproducibility also remains an issue, with device-to-device variability and heterogeneous receptor immobilization acknowledged by the authors.
Bottom line:
A potentially important technological step toward objective measurement of itch-related bioactivity, but not yet an AD diagnostic biomarker. Its real value may emerge from multiplexed “itch-print” panels incorporating several pruritic receptors and from validation across different itchy diseases, disease severities and treatment responses.